Nov 13, 2026 This Week in Cardiology

Listener feedback on the PROGRESS trial, the first Factor XI inhibitor improved, left bundle branch pacing, and statin discontinuation in older adults are the topics John Mandrola, MD, discusses in this week’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I Listener Feedback

• PROGRESS Trial https://www.nejm.org/doi/abs/10.1056/NEJMoa2607326

II FDA Approves Asundexian in Stroke

Will FDA-Approved Factor XIa Change Secondary Stroke Prevention? https://www.medscape.com/viewarticle/will-fda-approved-factor-xia-change-secondary-stroke-2026a100177u

• OCEANIC-STROKE Trial https://www.nejm.org/doi/10.1056/NEJMoa2513880
• Bleeding With Asundexian vs Placebo in Patients With Ischemic Stroke or High-Risk TIA https://pubmed.ncbi.nlm.nih.gov/42866879/
• OCEANIC-AF trial https://www.nejm.org/doi/full/10.1056/NEJMoa2407105

III Another Weak Pacing RCT – OptimPacing

The Best Pacing Strategy for AV Block: A Head vs Heart Analysis of The OptimPacing Trial https://www.medscape.com/viewarticle/best-pacing-strategy-av-block-head-vs-heart-analysis-2026a10016rn

• LEAP-Block Trial https://jamanetwork.com/journals/jama/fullarticle/2855975
• OptimPacing Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2612972

IV STREAM Trial

Statins Work in Older Adults, Statistics Be Damned: The STREAM Trial https://www.medscape.com/viewarticle/statins-work-older-adults-statistics-be-damned-stream-trial-2026a10016oo

• STREAM Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2606634
• STAREE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2607314

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.